MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 228 filers reported holding MIRATI THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,393,896 | +66.3% | 651,722 | +37.9% | 0.01% | +80.0% |
| Q2 2023 | $17,071,168 | +50.7% | 472,468 | +55.1% | 0.01% | +25.0% |
| Q1 2023 | $11,324,235 | +85845.9% | 304,594 | +4.7% | 0.00% | 0.0% |
| Q4 2022 | $13,176 | -99.9% | 290,859 | +40.8% | 0.00% | -33.3% |
| Q3 2022 | $14,424,000 | +20.6% | 206,504 | +15.9% | 0.01% | +50.0% |
| Q2 2022 | $11,959,000 | -23.3% | 178,142 | -6.0% | 0.00% | -20.0% |
| Q1 2022 | $15,584,000 | +24.5% | 189,529 | +122.2% | 0.01% | +25.0% |
| Q4 2021 | $12,517,000 | -7.1% | 85,314 | +12.0% | 0.00% | 0.0% |
| Q3 2021 | $13,473,000 | +55.5% | 76,175 | +42.1% | 0.00% | +33.3% |
| Q2 2021 | $8,662,000 | -8.1% | 53,619 | -2.6% | 0.00% | 0.0% |
| Q1 2021 | $9,428,000 | -0.3% | 55,058 | +27.9% | 0.00% | 0.0% |
| Q4 2020 | $9,453,000 | +150.9% | 43,039 | +89.7% | 0.00% | +50.0% |
| Q3 2020 | $3,768,000 | +48.2% | 22,693 | +1.9% | 0.00% | +100.0% |
| Q2 2020 | $2,543,000 | +73.8% | 22,278 | +17.1% | 0.00% | 0.0% |
| Q1 2020 | $1,463,000 | +454.2% | 19,032 | +829.3% | 0.00% | – |
| Q4 2019 | $264,000 | -95.4% | 2,048 | -97.2% | 0.00% | -100.0% |
| Q3 2019 | $5,692,000 | -25.3% | 73,065 | -1.3% | 0.00% | -33.3% |
| Q2 2019 | $7,624,000 | +39.8% | 74,015 | -0.5% | 0.00% | +50.0% |
| Q1 2019 | $5,452,000 | -47.6% | 74,377 | -69.7% | 0.00% | -60.0% |
| Q4 2018 | $10,398,000 | -26.7% | 245,124 | -18.6% | 0.01% | 0.0% |
| Q3 2018 | $14,180,000 | -8.5% | 301,057 | -4.2% | 0.01% | -16.7% |
| Q2 2018 | $15,495,000 | +50.9% | 314,306 | -6.1% | 0.01% | +50.0% |
| Q1 2018 | $10,271,000 | +68.2% | 334,567 | 0.0% | 0.00% | +33.3% |
| Q4 2017 | $6,106,000 | +55.0% | 334,567 | -0.6% | 0.00% | +50.0% |
| Q3 2017 | $3,939,000 | +441.1% | 336,667 | +68.7% | 0.00% | – |
| Q2 2017 | $728,000 | +7.5% | 199,563 | +53.3% | 0.00% | – |
| Q1 2017 | $677,000 | – | 130,186 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $116,595,216 | 81.37% |
| ORACLE INVESTMENT MANAGEMENT INC | 201,400 | $7,488,052 | 7.25% |
| Paradigm Biocapital Advisors LP | 1,396,779 | $51,932,243 | 4.92% |
| Octagon Capital Advisors LP | 750,000 | $27,885,000 | 4.01% |
| Boxer Capital, LLC | 2,000,000 | $74,360 | 3.65% |
| Artal Group S.A. | 1,537,709 | $57,172 | 3.40% |
| Avoro Capital Advisors LLC | 5,555,555 | $206,555,535 | 3.06% |
| RTW INVESTMENTS, LP | 3,643,114 | $135,450,979 | 2.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 244,000 | $9,071,920 | 2.53% |
| Kynam Capital Management, LP | 499,853 | $18,584,535 | 2.40% |